Safety of NTR-1011 in Healthy Adults and Adults With Lupus or Rheumatoid Arthritis

Trial details

Who runs it

Neutrolis

Trial code

NCT07237659

Record updated

20 July 2026

Original description

The goal of this clinical trial is to inform the safety and tolerability of NTR-1011 in treating adult patients diagnosed with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). It will also learn about the safety of NTR-1011 in healthy adult volunteers. The main questions it aims to answer are:Read full original descriptionShow less

A Phase 1a/b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of NTR-1011 in Healthy Adults and Adult Patients With Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA)

The goal of this clinical trial is to inform the safety and tolerability of NTR-1011 in treating adult patients diagnosed with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). It will also learn about the safety of NTR-1011 in healthy adult volunteers. The main questions it aims to answer are:

* What is the highest dose of NTR-1011 that is safe and well tolerated, when given under the skin or into a vein? * How does the body process NTR-1011, and how does NTR-1011 affect the body? * Does the body develop an immune response to NTR-1011? * Are there early signs that NTR-1011 may benefit patients with SLE or RA when added to their current standard-of-care treatment?

In the first part of the study (Phase 1a, now complete), researchers compared single doses of NTR-1011 to a placebo (a look-alike substance that contains no drug) in 48 healthy volunteers to see how the body tolerates and processes the drug.

In the current part of the study (Phase 1b, actively recruiting), all participants receive NTR-1011 in addition to their usual SLE or RA treatment; there is no placebo group. Up to 24 participants with moderate-to-severe SLE or RA will:

* Receive five weekly doses of NTR-1011 given directly into a vein (intravenous) * Continue their current standard-of-care treatment throughout the study * Be monitored for 4 weeks after their last dose * Be assigned to either the SLE group or the RA group (up to 12 patients each)

Inclusion: Healthy men and women, 18-55 years of age; Body mass index (BMI) between 17.0 and 30.0 kg/m²; Good general health, confirmed by medical history, physical exam, vital signs, ECG, and lab testing; Willing and able to use highly effective contraception during and after the study.

Exclusion: Use of an investigational drug within 30 days (or 5 half-lives) before dosing; Positive lupus-related antibodies (e.g., anti-dsDNA, anti-Smith) and low complement (C3/C4); On stable standard-of-care background therapy (e.g., antimalarials, low-dose corticosteroids, and at least one conventional DMARD); Seropositive for rheumatoid factor and/or anti-CCP antibodies; On stable standard-of-care background therapy (e.g., low-dose corticosteroids and at least one conventional DMARD); Use of an investigational drug within 30 days (or 5 half-lives) before dosing, or concurrent enrollment in another clinical trial; Receipt of a live vaccine within 4 weeks before screening or planned within 4 weeks after last dose; Major surgery within 8 weeks before screening or planned within 6 months after baseline; History of drug allergies or anaphylaxis to human, murine, or yeast proteins, monoclonal antibodies, or other allergens; Positive test for hepatitis B, hepatitis C, or HIV; Clinically significant heart, lung, digestive, blood, autoimmune, psychiatric, or other medical condition; Active disease at screening; Moderate-to-severe active disease; Known allergy or reaction to NTR-1011, placebo components, or related products; History of cancer within the past year (with limited exceptions); Significant kidney impairment, severe liver dysfunction, or severe lung disease; Uncontrolled high blood pressure or significant cardiovascular disease (e.g., recent heart attack or stroke, certain arrhythmias); Active, recurrent, or high-risk infection, including active or latent tuberculosis without appropriate treatment, opportunistic infections, or chronic hepatitis B; Recent symptoms of COVID-19 without a documented negative test; Significant central nervous system disease or pain-amplification conditions (e.g., epilepsy, fibromyalgia) that could interfere with study assessments; History of bone marrow, stem cell, or solid organ transplant (except cornea); Uncontrolled diabetes within the past 12 months (with some exceptions); History of a blood clot within the past 12 months (with some exceptions); Clinically significant abnormal lab values (e.g., liver enzymes, blood counts) or ECG findings; Clinically significant abnormal lab values (e.g., liver enzymes, blood counts) at screening; Men and women, 18-75 years of age; Up to date on age-appropriate vaccinations Additional Inclusion Criteria - RA Patients; Pregnant or breastfeeding; Uncontrolled high blood pressure; Poor venous access; Phase 1b - Adult Patients with SLE and RA (Actively Recruiting); General Inclusion Criteria (All Patients); Able to understand and sign informed consent, and comply with study visits; Willing and able to use highly effective contraception during and after the study; Additional Inclusion Criteria - SLE Patients; Diagnosis of SLE for at least 6 months, meeting 2019 EULAR/ACR classification criteria; Diagnosis of RA for at least 3 months, meeting 2010 ACR/EULAR classification criteria; Pregnant or breastfeeding.

Phase 1a - Healthy Volunteers (Completed, No Longer Enrolling).

ClinicalTrials.gov NCT07237659